vs
Five9, Inc.（FIVN）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Five9, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.4倍（$300.3M vs $207.3M），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 7.8%），Five9, Inc.自由现金流更多（$77.3M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 10.3%）
Five9是全球领先的云原生联络中心软件及解决方案供应商，服务零售、医疗、金融服务、科技等行业的各规模企业，提供全渠道客户互动、AI驱动自动化、劳动力管理、数据分析等工具，助力企业提升客户体验与运营效率。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
FIVN vs RARE — 直观对比
营收规模更大
FIVN
是对方的1.4倍
$207.3M
营收增速更快
RARE
高出18.1%
7.8%
自由现金流更多
FIVN
多$178.1M
$-100.8M
两年增速更快
RARE
近两年复合增速
10.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $300.3M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | 55.4% | — |
| 营业利润率 | 6.6% | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | 7.8% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.22 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FIVNRARE
| Q4 25 | $300.3M | $207.3M | ||
| Q3 25 | $285.8M | $159.9M | ||
| Q2 25 | $283.3M | $166.5M | ||
| Q1 25 | $279.7M | $139.3M | ||
| Q4 24 | $278.7M | $164.6M | ||
| Q3 24 | $264.2M | $139.5M | ||
| Q2 24 | $252.1M | $147.0M | ||
| Q1 24 | $247.0M | $108.8M |
净利润FIVNRARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $18.0M | $-180.4M | ||
| Q2 25 | $1.2M | $-115.0M | ||
| Q1 25 | $576.0K | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $-4.5M | $-133.5M | ||
| Q2 24 | $-12.8M | $-131.6M | ||
| Q1 24 | $-7.1M | $-170.7M |
毛利率FIVNRARE
| Q4 25 | 55.4% | — | ||
| Q3 25 | 55.0% | — | ||
| Q2 25 | 54.9% | — | ||
| Q1 25 | 55.0% | — | ||
| Q4 24 | 56.0% | — | ||
| Q3 24 | 53.8% | — | ||
| Q2 24 | 53.0% | — | ||
| Q1 24 | 53.6% | — |
营业利润率FIVNRARE
| Q4 25 | 6.6% | -54.7% | ||
| Q3 25 | 5.6% | -106.9% | ||
| Q2 25 | -0.6% | -64.8% | ||
| Q1 25 | -1.9% | -102.6% | ||
| Q4 24 | 1.5% | -74.3% | ||
| Q3 24 | -5.8% | -94.6% | ||
| Q2 24 | -7.7% | -79.1% | ||
| Q1 24 | -8.4% | -151.9% |
净利率FIVNRARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | 6.3% | -112.8% | ||
| Q2 25 | 0.4% | -69.0% | ||
| Q1 25 | 0.2% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | -1.7% | -95.7% | ||
| Q2 24 | -5.1% | -89.5% | ||
| Q1 24 | -2.9% | -156.8% |
每股收益（稀释后）FIVNRARE
| Q4 25 | $0.22 | $-1.28 | ||
| Q3 25 | $0.21 | $-1.81 | ||
| Q2 25 | $0.01 | $-1.17 | ||
| Q1 25 | $0.01 | $-1.57 | ||
| Q4 24 | $0.16 | $-1.34 | ||
| Q3 24 | $-0.06 | $-1.40 | ||
| Q2 24 | $-0.17 | $-1.52 | ||
| Q1 24 | $-0.10 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $232.1M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $785.8M | $-80.0M |
| 总资产 | $1.8B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FIVNRARE
| Q4 25 | $232.1M | $421.0M | ||
| Q3 25 | $193.4M | $202.5M | ||
| Q2 25 | $205.5M | $176.3M | ||
| Q1 25 | $370.3M | $127.1M | ||
| Q4 24 | $362.5M | $174.0M | ||
| Q3 24 | $291.0M | $150.6M | ||
| Q2 24 | $175.7M | $480.7M | ||
| Q1 24 | $240.2M | $112.3M |
股东权益FIVNRARE
| Q4 25 | $785.8M | $-80.0M | ||
| Q3 25 | $775.3M | $9.2M | ||
| Q2 25 | $717.4M | $151.3M | ||
| Q1 25 | $664.3M | $144.2M | ||
| Q4 24 | $622.2M | $255.0M | ||
| Q3 24 | $565.6M | $346.8M | ||
| Q2 24 | $525.9M | $432.4M | ||
| Q1 24 | $483.6M | $140.3M |
总资产FIVNRARE
| Q4 25 | $1.8B | $1.5B | ||
| Q3 25 | $1.8B | $1.2B | ||
| Q2 25 | $1.7B | $1.3B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | $2.1B | $1.5B | ||
| Q3 24 | $2.0B | $1.5B | ||
| Q2 24 | $1.9B | $1.6B | ||
| Q1 24 | $1.9B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $83.6M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $77.3M | $-100.8M |
| 自由现金流率自由现金流/营收 | 25.8% | -48.6% |
| 资本支出强度资本支出/营收 | 2.1% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $201.2M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流FIVNRARE
| Q4 25 | $83.6M | $-99.8M | ||
| Q3 25 | $59.2M | $-91.4M | ||
| Q2 25 | $35.1M | $-108.3M | ||
| Q1 25 | $48.4M | $-166.5M | ||
| Q4 24 | $49.8M | $-79.3M | ||
| Q3 24 | $41.1M | $-67.0M | ||
| Q2 24 | $19.9M | $-77.0M | ||
| Q1 24 | $32.4M | $-190.7M |
自由现金流FIVNRARE
| Q4 25 | $77.3M | $-100.8M | ||
| Q3 25 | $48.7M | $-92.7M | ||
| Q2 25 | $31.6M | $-110.7M | ||
| Q1 25 | $43.7M | $-167.8M | ||
| Q4 24 | $40.5M | $-79.5M | ||
| Q3 24 | $26.7M | $-68.6M | ||
| Q2 24 | $13.1M | $-79.0M | ||
| Q1 24 | $20.4M | $-193.9M |
自由现金流率FIVNRARE
| Q4 25 | 25.8% | -48.6% | ||
| Q3 25 | 17.0% | -58.0% | ||
| Q2 25 | 11.1% | -66.5% | ||
| Q1 25 | 15.6% | -120.5% | ||
| Q4 24 | 14.5% | -48.3% | ||
| Q3 24 | 10.1% | -49.2% | ||
| Q2 24 | 5.2% | -53.7% | ||
| Q1 24 | 8.3% | -178.2% |
资本支出强度FIVNRARE
| Q4 25 | 2.1% | 0.5% | ||
| Q3 25 | 3.7% | 0.8% | ||
| Q2 25 | 1.2% | 1.5% | ||
| Q1 25 | 1.7% | 1.0% | ||
| Q4 24 | 3.3% | 0.1% | ||
| Q3 24 | 5.4% | 1.2% | ||
| Q2 24 | 2.7% | 1.4% | ||
| Q1 24 | 4.8% | 3.0% |
现金转化率FIVNRARE
| Q4 25 | — | — | ||
| Q3 25 | 3.29× | — | ||
| Q2 25 | 30.38× | — | ||
| Q1 25 | 84.00× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FIVN
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
